Gentherm Reports 2019 First Quarter Results

Loading...
Loading...

Company Achieved Organic Automotive Revenue Growth Despite Industry Headwinds 
Secured $400 Million in Automotive Awards 
Maintains Full-Year 2019 Guidance and 2021 Outlook

NORTHVILLE, Mich., April 30, 2019 (GLOBE NEWSWIRE) -- Gentherm THRM, the global market leader and developer of innovative thermal management technologies, today announced its financial results for the first quarter ending March 31, 2019.

First Quarter Highlights

  • Product revenues of $257.9 million decreased 2.5% from $264.6 million in the 2018 first quarter. Excluding the impact of foreign currency translation, product revenues were flat year over year
  • Excluding the impact of foreign currency translation, divested assets and assets held for sale, product revenues increased 3.0% year over year
  • GAAP diluted earnings per share was $0.25 as compared with $0.35 for the prior-year period
  • Adjusted diluted earnings per share (see table herein), was $0.55. Adjusted diluted earnings per share in the prior-year period was $0.52
  • Secured automotive new business awards totaling $400 million in the quarter

Phil Eyler, the Company's President and CEO, said "I am pleased with the continued progress we are making with our focused growth strategy, validated by our improving operating performance, innovative technology advances and our first Automotive News PACE award. Despite the production headwinds in the industry, we achieved organic revenue growth in automotive, significantly outperforming our key markets. We delivered year-over-year revenue growth in Climate Control Seat ("CCS®") for the third consecutive quarter and secured $400 million of new awards from top auto makers around the world. In Medical, we delivered double-digit revenue growth both sequentially and year over year. In addition, we continue to improve our cost performance through the Fit-for-Growth program."

2019 First Quarter Financial Review

Product revenues for the first quarter of 2019 decreased $6.7 million, or 2.5%, as compared with the prior-year period, essentially due to a $6.6 million decrease in the Industrial segment. Excluding the impact of divested assets and assets held for sale, product revenues increased $0.8 million, or 0.3%, year over year. Excluding the impact of foreign currency translation, divested assets and assets held for sale, product revenues increased 3.0% year over year.

Automotive revenues were flat due to higher sales in Climate Control Seat ("CCS®") and Battery Thermal Management (BTM), offset by lower sales of seat heaters, steering wheel heaters and automotive cables. Adjusting for foreign currency translation, organic Automotive revenues increased 2.8% year over year.

Organic Automotive revenues grew despite lower than expected automotive production. When compared with IHS Markit's mid-February forecast for the first quarter of 2019, actual light vehicle production was approximately 2 percentage points below forecast. In addition, when compared to the first quarter of 2018, actual light vehicle production declined by approximately 6.7% in the Company's key markets.

The revenue decline in Industrial resulted primarily from lower revenues from the Cincinnati Sub-Zero ("CSZ") industrial chambers business, which was sold on February 1, 2019 and Global Power Technologies ("GPT"), which was classified as assets held for sale in the quarter. The decline was partially offset by a 12.3% growth in the medical business year over year.

See the "Revenues by Product Category" table enclosed herein for additional detail.

Gross margin rate declined to 29.2% in the current-year period, as compared with 30.7% in the prior-year period, primarily as a result of higher labor costs and the timing differences between annual customer price decreases compared to supplier cost reductions. These were partially offset by higher volume leverage and Fit-for-Growth cost reduction initiatives.

Net research and development expenses of $18.9 million in the 2019 first quarter decreased $4.4 million, or 18.9%. R&D expenses declined year over year, as a direct result of the Company's focused portfolio and Fit-for-Growth cost reduction initiatives. Additionally, R&D expenses declined year over year due to higher customer reimbursements.  

Selling, general and administrative expenses of $32.6 million in the 2019 first quarter decreased $3.8 million, or 10.5%, versus the prior-year period. The year-over-year decline was primarily driven by the impact of the Fit-for-Growth cost reduction initiatives and the sale of CSZ industrial chambers business in the quarter.  

During the quarter, the Company recognized $1.9 million in restructuring expenses which resulted from completed actions associated with its Fit-for-Growth initiatives. Total implemented actions to date are expected to deliver annualized savings of approximately $41 million. The Company has identified a total of $65 million of savings against its annualized target of $75 million by 2021.

As described more fully in the table included below, "Reconciliation of Net Income to Adjusted EBITDA," the Company recorded Adjusted EBITDA of $35.2 million in the 2019 first quarter compared with $34.5 million in the prior-year period, an increase of $0.7 million or 2.0%.

Income tax expense in the 2019 first quarter was $6.9 million, as compared with $3.0 million in the prior-year period. Adjusting for the $10.5 million non-deductible impairment loss, the effective tax rate for the quarter was 26.7%. This rate differed from the Federal statutory rate of 21%, primarily due to higher tax rates in foreign tax jurisdictions.

GAAP diluted earnings per share for the first quarter of 2019 was $0.25 compared with $0.35 for the prior-year period. Adjusted diluted earnings per share, excluding restructuring expenses, unrealized currency gain, and expenses and other impacts related to acquisitions (see table herein), was $0.55. Adjusted diluted earnings per share in the prior-year period was $0.52.

Guidance

The Company maintains its full-year 2019 guidance, excluding divested assets and assets held for sale, that was initially provided on its year-end 2018 earnings call on February 21, 2019:

  • Product revenues are expected to grow between 4% and 6% to a range of $1.01 billion to $1.04 billion
  • Operating expenses between 19% and 20% of product revenues
  • Gross margin rate between 28% and 30%
  • Adjusted EBITDA between 14% and 15% of product revenue
  • Full-year effective tax rate between 28% and 30%
  • Capital expenditures between $40 and $50 million

The Company also maintains the following outlook for 2021:

  • Product revenue growth of high single-digit CAGR for the 2018 to 2021 period
  • Operating expenses between 15% and 17% of product revenues
  • Gross margin rate between 30% and 32%
  • Adjusted EBITDA margin of high teens
  • ROIC of greater than 20%

Conference Call

As previously announced, Gentherm will conduct a conference call today at 8:00 am Eastern Time to review these results. The dial-in number for the call is 1-877-407-4018 (callers in the U.S.) or +1-201-689-8471 (callers outside this U.S.). The passcode for the live call is 13689375.

A live webcast and one-year archived replay of the call can be accessed on the Events page of the Investor section of Gentherm's website at www.gentherm.com.

A telephonic replay will be available at approximately 2 hours after the call until 11:59 pm Eastern Time on May 14, 2019. The replay can be accessed by dialing 1-844-512-2921 (callers in the U.S.), or +1-412-317-6671 (callers outside the U.S.). The passcode for the replay is 13689375.

Loading...
Loading...

Investor Relations Contact
Yijing Brentano
investors@gentherm.com
(248) 308-1702

Media Contact
Melissa Fischer
media@gentherm.com
248.289.9702

About Gentherm

Gentherm THRM is a global developer and marketer of innovative thermal management technologies for a broad range of heating and cooling and temperature control applications. Automotive products include variable temperature Climate Control Seats, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery thermal management systems, cable systems and other electronic devices. Medical products include patient temperature management systems. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets. Gentherm has over 13,000 employees in facilities in the United States, Germany, Canada, China, Hungary, Japan, Korea, Macedonia, Malta, Mexico, United Kingdom, Ukraine, and Vietnam. For more information, go to www.gentherm.com.

Except for historical information contained herein, statements in this release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent Gentherm Incorporated's goals, beliefs, plans and expectations about its prospects for the future and other future events. The forward-looking statements included in this release are made as of the date hereof or as of the date specified and are based on management's current expectations and beliefs. Such statements are subject to a number of important assumptions, risks, uncertainties and other factors that may cause the Company's actual performance to differ materially from that described in or indicated by the forward-looking statements. Those risks include, but are not limited to, risks that new products may not be feasible, sales may not increase, additional financing requirements may not be available, new competitors may arise or customers may develop their own products to replace the Company's products, currency exchange rates may change unfavorably, pricing pressures from customers may increase, the Company's workforce and operations could be disrupted by civil or political unrest in the countries in which the Company operates, free trade agreements may be altered in a manner adverse to the Company, cost-savings measures may not be achievable or may need to be reversed, assets held for sale may not be sold quickly or at all, the Company may be unable to repurchase its shares of common stock at favorable prices or at all, due to market conditions, applicable legal requirements, debt covenants or other restrictions, compliance with covenants and other restrictions under the Company's credit facility, medical device regulations could change in an unfavorable manner, oil and gas prices could fluctuate causing adverse consequences, and other adverse conditions in the industries in which the Company operates may negatively affect its results. In addition, such forward-looking statements do not include the potential impact of any business combinations, acquisitions, divestitures, strategic investments and other significant transactions that may be completed after the date hereof.

The foregoing risks should be read in conjunction with other cautionary statements included herein, as well as in the Company's annual report on Form 10-K for the year ended December 31, 2018 and subsequent reports filed with the Securities and Exchange Commission. Except as required by law, the Company expressly disclaims any obligation or undertaking to update any forward-looking statements to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

GENTHERM INCORPORATED
CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share data) 
(Unaudited)
 
  Three Months Ended
March 31,
   
  2019  2018   
Product revenues $257,921  $264,586   
Cost of sales  182,614   183,344   
Gross margin  75,307   81,242   
Operating expenses:          
Net research and development expenses  18,897   23,304   
Selling, general and administrative expenses  32,613   36,424   
Acquisition transaction expenses  38      
Restructuring expenses  1,914   865   
    Total operating expenses  53,462   60,593   
Operating income  21,845   20,649   
Interest expense  (1,368)  (1,180)  
Foreign currency gain (loss)  203   (4,578)  
Gain on sale of business  4,970      
Impairment loss  (10,484)     
Other income  143   1,111   
Earnings before income tax  15,309   16,002   
Income tax expense  6,895   3,036   
Net income $8,414  $12,966   
Basic earnings per share $0.25  $0.35   
Diluted earnings per share $0.25  $0.35   
Weighted average number of shares – basic  33,573   36,766   
Weighted average number of shares – diluted  33,733   36,873   


GENTHERM INCORPORATED
REVENUE BY PRODUCT CATEGORY
(Unaudited, in thousands)
 
  Three Months Ended
March 31,
       
  2019  2018  %
Diff.
  
Climate Control Seat (CCS®) $94,354  $88,218   7.0 % 
Seat Heaters  73,920   84,220   (12.2)% 
Steering Wheel Heaters  16,970   17,557   (3.3)% 
Automotive Cables  23,749   26,865   (11.6)% 
Battery Thermal Management (BTM)  10,745   4,161   158.2 % 
Electronics  12,852   15,188   (15.4)% 
Other Automotive  9,767   6,212   57.2 % 
Subtotal Automotive $242,357  $242,421    % 
Remote Power Generation (GPT)  3,959   4,662   (15.1)% 
Industrial Chambers  3,418   10,213   (66.5)% 
Gentherm Medical  8,187   7,290   12.3 % 
Subtotal Industrial $15,564  $22,165   (29.8)% 
Total Company $257,921  $264,586   (2.5)% 
 

 

 
              
Total Core Businesses (Automotive and Gentherm Medical) $250,544  $249,711   0.3 % 
 


GENTHERM INCORPORATED
RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA
(Unaudited, in thousands)
 
  Three Months Ended
March 31,
 
  2019  2018 
Net income $8,414  $12,966 
Add Back:        
  Income tax expense  6,895   3,036 
  Interest expense  1,368   1,180 
  Depreciation and amortization  10,980   12,820 
Adjustments:        
Restructuring expenses  1,914   865 
Impairment of assets held for sale  10,484    
Gain on sale of a business  (4,970)   
Acquisition transaction expense  38    
Unrealized currency (gain)/loss  (994)  3,642 
CFO transition expenses  1,065    
Adjusted EBITDA $35,194  $34,509 

Use of Non-GAAP Financial Measures
In evaluating its business, Gentherm considers and uses Adjusted EBITDA as a supplemental measure of its operating performance. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, deferred financing cost amortization, transaction expenses, debt retirement expenses, impairment of assets held for sale, restructuring expenses, unrealized currency gain or loss and unrealized revaluation of derivatives. Management believes that Adjusted EBITDA is a meaningful measure of liquidity and the Company's ability to service debt because it provides a measure of cash available for such purposes. Management provides an Adjusted EBITDA measure so that investors will have the same financial information that management uses with the belief that it will assist investors in properly assessing the Company's performance on a period-over-period basis.

The term Adjusted EBITDA is not defined under GAAP, and is not a measure of operating income, operating performance or liquidity presented in accordance with GAAP. Adjusted EBITDA has limitations as an analytical tool, and when assessing the Company's operating performance, investors should not consider Adjusted EBITDA in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with GAAP. Gentherm compensates for these limitations by relying primarily on its GAAP results and using Adjusted EBITDA only supplementally.


GENTHERM INCORPORATED
ACQUISITION TRANSACTION EXPENSES, PURCHASE ACCOUNTING IMPACTS
AND OTHER EFFECTS
(Unaudited and in thousands, except per share data)
 
   Three Months Ended
    March 31, 
  Future Full Year Periods (estimated) 
  
    2019 
      2018        2019        2020        2021        2022   Thereafter
        
Transaction related current expenses       
Acquisition transaction expenses   38    –    38    –    –    –    – 
Non-cash purchase accounting impacts       
Customer relationships amortization   1,828    2,665    7,251    5,991    5,461    5,143    18,574 
Technology amortization   482    998    1,913    1,909    1,901    1,843    4,759 
Inventory value adjustment   39    30    39    –    –    –    – 
Trade name amortization   –    –    –    –    –    –    – 
Other effects       
Restructuring expenses   1,914    865    1,914    –    –    –    – 
Gain on sale of a business   (4,970)   –    (4,970)   –    –    –    – 
Impairment loss   10,484    –    10,484    –    –    –    – 
Unrealized currency (gain)/loss   (994)   3,642    (994)   –    –    –    – 
CFO Transition     1,065      –      1,065      –      –      –      – 

Total acquisition transaction expenses, purchase accounting impacts and other effects

$


    9,886

 
 
$

    8,200
 
$

    16,740
 
$

    7,900
 
$

    7,362
 
$

    6,986
 
$

    23,333
 
Tax effect of above     212      (2,098)     (1,465)     (1,950)     (1,825)     (1,735)     (5,791)
Net income effect$    10,098 $    6,102 $    15,275 $    5,950 $    5,537 $    5,251 $    17,542 
        
Earnings per share – difference       
Basic$    0.30 $    0.17    –    –    –    –    – 
Diluted$    0.30 $    0.17    –    –    –    –    – 
Adjusted earnings per share       
Basic$    0.55 $    0.52    –    –    –    –    – 
Diluted$    0.55 $    0.52    –    –    –    –    – 
        


GENTHERM INCORPORATED
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
(Unaudited)
 
 March 31,
2019
  December 31,
2018
 
ASSETS       
Current Assets:       
Cash and cash equivalents$38,769  $39,620 
Restricted cash 2,500    
Accounts receivable, less allowance of $1,068 and $851, respectively 175,044   166,858 
Inventory:       
    Raw materials 66,316   61,679 
    Work in process 4,830   5,939 
    Finished goods 40,979   44,917 
        Inventory, net 112,125   112,535 
Derivative financial instruments 857   92 
Prepaid expenses and other assets 55,577   54,271 
Assets held for sale 17,009   69,699 
    Total current assets 401,881   443,075 
Property and equipment, net 168,371   171,380 
Goodwill 54,721   55,311 
Other intangible assets, net 53,188   56,385 
Operating lease right-of-use assets 14,058    
Deferred financing costs 575   647 
Deferred income tax assets 61,032   64,024 
Other non-current assets 9,220   12,225 
   Total assets$763,046  $803,047 
LIABILITIES AND SHAREHOLDERS' EQUITY       
Current Liabilities:       
Accounts payable$91,286  $93,113 
Accrued liabilities 60,907   65,808 
Current lease liabilities 4,203    
Current maturities of long-term debt 2,949   3,413 
Liabilities held for sale 7,009   13,062 
      Total current liabilities 166,354   175,396 
Pension benefit obligation 6,755   7,211 
Non-current lease liabilities 9,307    
Long-term debt, less current maturities 97,604   136,477 
Deferred income tax liabilities 1,649   1,177 
Other non-current liabilities 2,890   3,087 
    Total liabilities 284,559   323,348 
Shareholders' equity:       
Common Stock:       
    No par value; 55,000,000 shares authorized, 33,653,179 and 33,856,629 issued and outstanding at March 31, 2019 and December 31, 2018, respectively 134,486   140,300 
Paid-in capital 14,513   14,934 
Accumulated other comprehensive loss (43,152)  (39,500)
Accumulated earnings 372,640   363,965 
     Total shareholders' equity 478,487   479,699 
     Total liabilities and shareholders' equity$763,046  $803,047 


GENTHERM INCORPORATED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
 
 Three Months Ended March 31, 
 2019  2018 
Operating Activities:       
Net income$8,414  $12,966 
Adjustments to reconcile net income to cash provided by operating activities:       
    Depreciation and amortization 11,052   12,892 
    Deferred income taxes 1,749   (707)
    Stock compensation 1,968   2,202 
    Defined benefit plan (income) expense (617)  298 
    Provision of doubtful accounts 229   41 
    Loss on sale of property and equipment 178   85 
    Operating lease expense 1,333    
    Impairment loss 10,484    
    Gain on sale of business (4,970)   
    Changes in operating assets and liabilities:       
          Accounts receivable (8,293)  (9,691)
          Inventory (229)  1,903 
          Prepaid expenses and other assets (5,553)  (4,881)
          Accounts payable (2,079)  1,290 
          Accrued liabilities (6,785)  (10,808)
Net cash provided by operating activities 6,881   5,590 
Investing Activities:       
Proceeds from the sale of property and equipment 28    
Proceeds from the sale of a business 47,500    
Final payment for acquisition of subsidiary, net of cash acquired    (15)
Purchases of property and equipment (5,150)  (8,378)
    Net cash provided by (used in) investing activities 42,378   (8,393)
Financing Activities:       
Borrowing of debt 10,428    
Repayments of debt (49,627)  (35,492)
Cash paid for the cancellation of restricted stock (376)  (659)
Proceeds from the exercise of Common Stock options 214   751 
Repurchase of Common Stock (8,040)   
          Net cash used in financing activities (47,401)  (35,400)
          Foreign currency effect (209)  5,513 
          Net increase (decrease) in cash, cash equivalents and restricted cash 1,649   (32,690)
          Cash, cash equivalents and restricted cash at beginning of period 39,620   103,172 
          Cash, cash equivalents and restricted cash at end of period$41,269  $70,482 
Supplemental disclosure of cash flow information:       
Cash paid for taxes$3,466  $6,870 
Cash paid for interest$1,252  $981 
Supplemental disclosure of non-cash transactions:       
Common Stock issued to Board of Directors and employees$1,581  $1,362 


 

Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...